Long-term Efficacy and Safety of Repeated Ofatumumab Treatment Courses in RA Patients Who Previously Received Ofatumumab or Placebo in Trial Hx-CD20-403

PHASE2TerminatedINTERVENTIONAL
Enrollment

124

Participants

Timeline

Start Date

January 1, 2008

Primary Completion Date

May 25, 2011

Study Completion Date

March 19, 2013

Conditions
Arthritis, Rheumatoid
Interventions
DRUG

ofatumumab

1000 mL dilution of 35mls ofatumumab in sterile, pyrogen free, 0.9% NaCl

Trial Locations (10)

2100

GSK Investigational Site, Copenhagen

2600

GSK Investigational Site, Glostrup Municipality

2900

GSK Investigational Site, Hellerup

9700

GSK Investigational Site, Szombathely

10003

GSK Investigational Site, New York

16635

GSK Investigational Site, Duncansville

33334

GSK Investigational Site, Fort Lauderdale

90095

GSK Investigational Site, Los Angeles

02-256

GSK Investigational Site, Warsaw

IP4 5PD

GSK Investigational Site, Ipswich

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY